Arch Therapeutics Inc (OTCMKTS:ARTH) is a micro-cap name in the medical device space that has started to really get moving again of late. One piece of the puzzle is the company’s aggressive schedule of conference appearances over coming weeks. That is usually a good sign for healthcare names, and the market is responding.
We covered ARTH stock last Fall, noting that it appears to be acting with confidence and has not abused investors on its path to its current status. The narrative here is an easy one to get excited about: This company developed a novel approach to stop bleeding and control leaking during surgery and trauma care. For a sense of the opportunity in this niche, consider that well over half a million people die each year in surgery in the US alone. The most common cause is blood loss. ARTH has developed the AC5 Surgical Hemostatic Device, which has been proven to stop bleeding in an average of 10 seconds.
Arch Therapeutics Inc (OTCMKTS:ARTH) bills itself as a company that operates as a life science medical device maker. The company focuses on developing products based on a novel technology to stop bleeding and control leaking during surgery and trauma care.
Its lead product candidate is AC5 Surgical Hemostatic Device, a biocompatible synthetic peptide comprising naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. It’s an innovative self-assembling peptide technology platform but is still in development at this point.
The company was founded in 2006 and is based in Framingham, Massachusetts.
According to company materials, “Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch’s flagship development stage product candidates, known as AC5 Surgical Hemostatic Device™ and AC5 Topical Hemostatic Device™, are being designed to achieve hemostasis in minimally invasive and open surgical procedures.”
Find out when ARTH stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, this company is setting out on what amounts to a press tour over coming weeks.
The company just announced that it will be featured as a presenting company at NobleCon13: Noble Financial Capital Markets’ Thirteenth Annual Equity Conference in Boca Raton, Florida. Chief Executive Officer, Terrence W. Norchi, MD, is scheduled to present on Tuesday, January 31 at 2:00 PM ET. He will be available to participate in meetings with investors who are registered to attend the conference.
In addition, just days earlier, ARTH announced that it will present at the Source Capital Group’s 2017 Disruptive Growth & Healthcare Conference. Chief Executive Officer Terrence W. Norchi, MD will provide a corporate update, discuss near-term milestones, and meet with investors. The conference will be held at the Convene Conference Center, 730 3rd Avenue in New York City.
Recent action has seen 31% added to share values of the name over the past month of action. The situation may be worth watching. ARTH has a track record that includes a number of dramatic bounces. Moreover, the name has witnessed a pop in interest, as transaction volume levels have recently pushed exceeding 100% over what the stock has registered over the longer term. Since we last covered the name, ARTH stock has moved 33% higher.
The Company also recently reported successful results from its initial study of safety and efficacy for the flagship product.
The primary endpoint was safety throughout the surgical procedure and until the end of a 30-day follow-up period post procedure. The primary objective was met, as the safety outcomes of both the AC5 treatment group and the control group were similar. No serious adverse events were reported. A secondary endpoint was performance as assessed by time to hemostasis.
The median time to hemostasis of wounds in the AC5 treatment group was 41% faster than for those in the control group. This result was statistically significant.
An additional secondary endpoint of healing of treated wounds was assessed as measured by the ASEPSIS wound score at Days 7 and 30. All AC5-treated wounds healed satisfactorily as per wound healing scoring criteria.
At this time, carrying a capital value in the market of $108.1M, ARTH has a significant war chest ($5M) of cash on the books, which must be weighed relative to about $900K in total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. We will update the story again soon as further details emerge. For continuing coverage on shares of ARTH stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!